Lucid Diagnostics Inc. (LUCD)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 1,163 | 828 | 1,172 | 976 |
| Sales and marketing | 4,007 | 4,069 | 4,056 | 4,210 |
| Research and development | 1,255 | 1,428 | 1,666 | 1,372 |
| General and administrative | 5,617 | 6,162 | 5,355 | 4,867 |
| Amortization of acquired intangible assets | 105 | 105 | 105 | 105 |
| Cost of revenue | 1,563 | 1,551 | 1,684 | 1,614 |
| Total operating expenses | 12,547 | 13,315 | 12,866 | 12,168 |
| Operating loss | -11,384 | -12,487 | -11,694 | -11,192 |
| Interest income | 110 | 66 | 81 | 107 |
| Interest expense | 6 | 9 | 1 | 6 |
| Debt extinguishments loss - senior secured convertible note | - | - | -435 | -513 |
| Change in fair value - senior secured convertible note | -6,841 | 14,478 | 322 | -599 |
| Other income (expense), net | 6,945 | -14,421 | -677 | 187 |
| Loss before provision for income tax | -4,439 | -26,908 | -12,371 | -11,005 |
| Provision for income taxes | - | - | - | - |
| Net loss attributable to lucid diagnostics inc | -4,439 | -26,908 | -12,371 | -11,005 |
| Less deemed dividend on series a and series a-1 convertible preferred stock | - | - | - | - |
| Less series b and series b-1 convertible preferred stock dividends earned | 3,449 | 9,110 | - | - |
| Net loss attributable to lucid diagnostics inc. common stockholders | -7,888 | -36,018 | -12,371 | -11,005 |
| Net loss per share attributable to lucid diagnostics inc. common stockholders - basic | -0.08 | -0.52 | -0.25 | -0.23 |
| Net loss per share attributable to lucid diagnostics inc. common stockholders - diluted | -0.08 | -0.52 | -0.25 | -0.23 |
| Weighted average common shares outstanding, basic | 98,989,161 | 68,796,392 | 50,374,146 | 48,212,040 |
| Weighted average common shares outstanding, diluted | 98,989,161 | 68,796,392 | 50,374,146 | 48,212,040 |